肾小管来源癌报告数据集:ICCR推荐
国际癌症报告合作组织(ICCR)基于英国、澳新和CAP的报告规范,制定了肾小管来源癌肾切除术后的最小结构化报告模板,采纳2012 ISUP温哥华共识和2016 WHO蓝皮书。数据集将报告要素分为必需和推荐两类,旨在标准化信息并促进国际研究。
要点
- 必需要素包括侧别、术式、肿瘤大小、类型、WHO/ISUP分级、肉瘤样/横纹肌样形态、坏死、侵犯范围、淋巴结和切缘状态、TNM分期及并存病变。
- 推荐要素包括术前治疗、实验用组织详情、肿瘤取材block标识、肉瘤样/横纹肌样成分范围、坏死范围、肾静脉壁侵犯、脉管侵犯及淋巴结转移灶大小和结外扩展。
- 该数据集预期用于常规临床实践以指导治疗和预后预测,并促进国际研究合作。
核心结论
- ICCR发布了肾小管来源癌肾切除术后的结构化报告数据集,包含必需和推荐报告要素,旨在标准化报告并支持患者管理和国际研究。
研究设计与样本
- 基于英国皇家病理学院、澳新皇家病理学院和美国病理学家协会已发布的报告协议,并纳入2012 ISUP温哥华共识和2016 WHO蓝皮书建议,制定国际适用的最小结构化报告模板。
主要发现
- 报告要素分为必需和推荐两类;必需要素包括标本侧别、手术操作、附着结构、肿瘤多灶性、肿瘤尺寸、肿瘤类型、WHO/ISUP分级、肉瘤样/横纹肌样形态、肿瘤坏死、侵犯范围、淋巴结状态、手术切缘状态、AJCC TNM分期和并存病理。
- 推荐要素包括术前治疗、提交前为实验目的取除组织的详情、肿瘤block识别key的部位、肉瘤样和/或横纹肌样成分的范围、坏死范围、肾静脉壁内肿瘤存在、淋巴血管侵犯和淋巴结状态(最大灶大小和结外扩展)。
关键数值与推荐
- 必需要素:标本侧别、手术操作、附着结构、肿瘤多灶性、肿瘤尺寸、肿瘤类型、WHO/ISUP分级、肉瘤样/横纹肌样形态、肿瘤坏死、侵犯范围、淋巴结状态、手术切缘状态、AJCC TNM分期、并存病理。
- 推荐要素:术前治疗、实验用组织详情、肿瘤block识别key部位、肉瘤样/横纹肌样成分范围、坏死范围、肾静脉壁肿瘤、淋巴血管侵犯、淋巴结状态(最大灶大小和结外扩展)。
临床怎么用
- 在肾小管来源癌肾切除标本的病理报告中采用该结构化数据集,确保必需要素完整,并尽可能纳入推荐要素,以标准化报告内容并支持临床决策和预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The International Collaboration on Cancer Reporting (ICCR) has provided detailed data sets based upon the published reporting protocols of the Royal College of Pathologists, the Royal College of Pathologists of Australasia and the College of American Pathologists. METHODS AND RESULTS: The data set for carcinomas of renal tubular origin treated by nephrectomy was developed to provide a minimum structured reporting template suitable for international use, and incorporated recommendations from the 2012 Vancouver Consensus Conference of the International Society of Urological Pathology (ISUP) and the fourth edition of the World Health Organisation Bluebook on tumours of the urinary and male genital systems published in 2016. Reporting elements were divided into those, which are required and recommended components of the report. Required elements are: specimen laterality, operative procedure, attached structures, tumour focality, tumour dimension, tumour type, WHO/ISUP grade, sarcomatoid/rhabdoid morphology, tumour necrosis, extent of invasion, lymph node status, surgical margin status, AJCC TNM staging and co-existing pathology. Recommended reporting elements are: pre-operative treatment, details of tissue removed for experimental purposes prior to submission, site of tumour(s) block identification key, extent of sarcomatoid and/or rhabdoid component, extent of necrosis, presence of tumour in renal vein wall, lymphovascular invasion and lymph node status (size of largest focus and extranodal extension). CONCLUSIONS: It is anticipated that the implementation of this data set in routine clinical practice will inform patient treatment as well as provide standardised information relating to outcome prediction. The harmonisation of data reporting should also facilitate international research collaborations.
引用
- Delahunt B, Srigley JR, Judge MJ, et al. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2019. PMID: 30325065. doi:10.1111/his.13754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。